| ²é¿´: 1469 | »Ø¸´: 4 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
sophielajľ³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ŵ»ªÎªÊ²Ã´ÔÚÃÀ¹úÍ£Ö¹ÏúÊÛ¸ñÁÐÎÀ½ºÄÒ¼Á£¿
|
|
ÈçÌâ¡¡![]() ![]() ![]() ÕÒÁË´ó°ëÌ죬ÕÒµ½Ò»Ìõ¿´ËÆÓÐÓÃȴûÓõÄÐÅÏ¢£º Hyman, Phelps & McNamara, PC, submitted a citizen petition dated June 3, 2010 (Docket No. FDA¨C2010¨CP¨C0275), under 21 CFR 10.30, requesting that the Agency determine whether GLEEVEC (imatinib mesylate) Capsules, 50 mg and 100 mg, were withdrawn from sale for reasons of safety or effectiveness. After considering the citizen petition and reviewing Agency records, FDA has determined under ¡ì 314.161 that GLEEVEC (imatinib mesylate) Capsules, 50 mg and 100 mg were not withdrawn for reasons of safety or effectiveness. £¨ÃÀ¹úÁª°î¹«±¨£¨2010-12-7£©£© |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸ÌìÖÐÒ½ÖÐҩѧר˶£¬Ï£ÍûÓÐbÇøµÄÀÏʦ¿ÉÒÔ¿¼ÂÇÒ»ÏÂÎÒ
ÒѾÓÐ1È˻ظ´
µ÷¼Á
ÒѾÓÐ2È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ249È˻ظ´
ҩѧѧ˶326Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
26Ä격ʿÉêÇë
ÒѾÓÐ20È˻ظ´
Ò©Àíѧ¡¢ÁÙ´²Ò©Ñ§·½Ïò µ÷¼Á
ÒѾÓÐ1È˻ظ´
ÇóÖú ±½Á×Áò°·JP
ÒѾÓÐ0È˻ظ´
100½ð±Ò °¢ÄªÎ÷ÁÖ¿ËÀάËá¼ØÆ¬BPÒ©µäÖÐÌáµ½µÄ¿ËÀάËá¾ÛºÏÎï¾ßÌå½á¹¹Ê½ÊÇɶ£¿
ÒѾÓÐ2È˻ظ´
ÉÅʳ²¹³ä¼ÁºÏ¹æÐÔ½»Á÷
ÒѾÓÐ0È˻ظ´
ÖйúÒ½Ò©ÐÐÒµ·¢Õ¹ÏÖ×´£º±ê×¼Æ·ÍÆ¶¯Ò©Æ·¼ì²âˮƽÌáÉý
ÒѾÓÐ0È˻ظ´
wnting
ÖÁ×ðľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 12556.2
- Ìû×Ó: 340
- ÔÚÏß: 119.1Сʱ
- ³æºÅ: 423361
- ×¢²á: 2007-07-21
- ÐÔ±ð: GG
- רҵ: ÁÙ´²Ò©Àí
4Â¥2013-09-11 16:30:45
wnting
ÖÁ×ðľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 12556.2
- Ìû×Ó: 340
- ÔÚÏß: 119.1Сʱ
- ³æºÅ: 423361
- ×¢²á: 2007-07-21
- ÐÔ±ð: GG
- רҵ: ÁÙ´²Ò©Àí
2Â¥2013-09-10 13:59:17
sophielaj
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3995.6
- ºì»¨: 1
- Ìû×Ó: 53
- ÔÚÏß: 93Сʱ
- ³æºÅ: 602326
- ×¢²á: 2008-09-14
- ÐÔ±ð: MM
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
3Â¥2013-09-11 09:00:57
sophielaj
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3995.6
- ºì»¨: 1
- Ìû×Ó: 53
- ÔÚÏß: 93Сʱ
- ³æºÅ: 602326
- ×¢²á: 2008-09-14
- ÐÔ±ð: MM
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
5Â¥2013-09-12 16:27:13














»Ø¸´´ËÂ¥